There is growing evidence that statins may protect against the development or worsening of open-angle glaucoma (OAG). As researchers plan clinical trials to more definitively study whether statins indeed protect against OAG, it would be helpful to know whether specific daily dosages or types of statin confer a greater protective effect than others.
found that persons with hyperlipidemia who took statins continuously for 2 years had an 8% decreased OAG risk relative to nonusers (P = .006) and a 9% decreased risk of progressing from glaucoma suspect to OAG compared with nonusers (P = .006). 11 While these findings support other studies demonstrating that statins may help protect against OAG, 1-10 the definitive means of assessing the role of statins in glaucoma care is to perform a randomized clinical trial (RCT). Before embarking on an RCT, there are additional questions that can be explored using claims data. Here, we use the same data source as our previous study 11 to assess whether (1) the apparent beneficial effect of statins on OAG risk is limited to persons with elevated low-density lipoprotein (LDL) cholesterol levels, (2) the use of a particular daily dosage of statin is required to achieve a beneficial effect, and (3) the use of a particular statin type protects best against OAG.
Methods
We used the Clinformatics DataMart (OptumInsight), a claims database of enrollees in a nationwide managed-care network. To keep analyses consistent with our past work, 11 we used data from January 2001 to December 2009. This database captures ocular and nonocular diagnoses by using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 12 codes and contains information on enrollees' sociodemographic characteristics, outpatient prescriptions filled, and laboratory test results. All enrollees in the medical plan were also in the pharmacy plan. The University of Michigan Institutional Review Board approved this study, and because data were taken from a deidentified database, informed consent was waived. We identified enrollees 60 years and older with hyperlipidemia (ICD-9-CM code 272.x) and no preexisting OAG diagnosis in the previous 2 years. Those with less than 2 years of plan enrollment, any noncontinuous enrollment, or no ophthalmologist or optometrist visits were excluded. Each enrollee had to have at least 1 LDL measurement within 6 months of the index date (2 years after plan enrollment). Multivariable Cox proportional hazards regression modeling assessed the hazard for developing OAG. We created 3 models. For each model, enrollees were observed from the index date until OAG onset or their last eye-care visit. The outcome of interest was diagnosis of OAG (ICD-9-CM codes 365.1, 365.10-12, and 365.15). Covariates included sociodemographic characteristics (age, sex, race/ethnicity, household net worth, education level, and region of residence), medical comorbidities (systemic hypotension, obesity, sleep apnea, migraine, diabetes, and hypertension), ocular comorbidities (cataract, pseudophakia/ aphakia, macular degeneration, and diabetic retinopathy), other cholesterol-lowering medication use, and Charlson Comorbidity Index score, 13 which measures disease burden.
Additional methodological details appear elsewhere. Findings This study found that after accounting for baseline low-density lipoprotein levels, persons who filled prescriptions for statins continuously for 2 years had a 21% reduced risk of glaucoma vs nonusers. There was no additional protective effect associated with taking the highest dosage of statins (80 mg) compared with a lower dosage (40 mg) or with other types compared with atorvastatin.
Meaning When planning clinical trials to study the effect of statins on glaucoma, it is reasonable to use a generic statin like atorvastatin and a 40mg or lower daily dosage.
remaining patients (4942 [31.1%]) used multiple agents. The mean (SD) LDL value among patients was 112 (33) mg/dL (to convert to millimoles per liter, multiply by 0.0259).
After adjusting for possible confounders and baseline LDL level, every additional month of statin use was associated with a 1% decreased hazard for OAG (hazard ratio [HR], 0.990; 95% CI, 0.983-0.998; P = .02). Thus, those who took statins continuously for 2 years had a 21% decreased hazard for OAG compared with nonusers. The difference between users and nonusers of other cholesterol-lowering medications was not significant for OAG risk (HR, 1.00; 95% CI, 0.99-1.01; P = .69). The OAG hazard among persons in the lowest baseline LDL quartile did not differ with persons in any other LDL quartile (P > .05 for all comparisons) ( Table 2 
Discussion
This study offers useful information about key parameters to consider in planning an RCT to test whether statins protect against OAG development or progression. The risk of developing OAG does not appear to be associated with the daily dosage consumed (10, 20, or 80 mg vs 40 mg). Because the risk of adverse effects rises with increasing daily statin dosage, 14 exposing RCT participants to a relatively high dosage of 80 mg would seem unnecessary. A daily dosage of 40 mg or less may be more appropriate. Additionally, compared with atorvastatin, no other statin type was more protective against OAG. Because some statins are costlier than others, it seems reasonable to select an inexpensive generic agent like atorvastatin for an RCT. Finally, we found that the apparent protective effect of statins against OAG observed in our earlier study appears to persist in the present analyses after adjusting for baseline LDL levels. There was no significant difference in OAG risk between those in the highest and lowest baseline LDL quartiles after we accounted for use of statin and other cholesterollowering medications. This suggests that the potential beneficial effect of statins on OAG risk is associated less with lowering lipid levels and more with other properties of statins, such as outflow enhancement by affecting rho kinase activity or neuroprotection. [3] [4] [5] In fact, the risk reduction of 2 years' continuous statin use was 8% before baseline LDL level adjustment and 21% afterward.
Limitations
This study had limitations. Unfortunately, claims data lack information on clinical variables, such as intraocular pressures, to consider in our models. Also, we assume that filling medication prescriptions is a reasonable surrogate for medication consumption. However, if persons are filling prescriptions but not actually taking the medications, then this would bias the results to the null.
Conclusions
These study findings provide researchers with useful information about an appropriate daily dosage and type of statin to select for an RCT to explore whether statins can prevent the development of OAG or halt OAG progression. Survival probability is the unadjusted probability of not developing open-angle glaucoma by that time. Although not shown, the confidence bands for the 4 daily dosages overlap for nearly the entire length of follow-up, indicating no statistically significant differences.
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